Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help kids with severe psoriasis

NCT ID NCT04772079

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

This study tests a drug called deucravacitinib in children and teens aged 4 to 18 with moderate to severe plaque psoriasis. The trial will measure how the drug works in the body, how well it clears psoriasis, and its safety over up to 5 years. Participants are randomly assigned to receive either the drug or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucravacitinib (a pill that targets the immune system to reduce inflammation)
What this could lead to
If successful, this could provide a new oral treatment option for children and teens with moderate to severe plaque psoriasis, potentially improving skin clearance and quality of life.
What could go wrong
This is still an early-stage pediatric study (Phase 3) with a small number of participants (153). The drug may not work as well in children as in adults, and long-term safety, including effects on growth and development, is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 153 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2021

Expected to finish

Sep 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Males and females aged 12 to \<18 years for Cohort 1. Males and females aged 4 to \<12 years for Cohort 2. * Plaque psoriasis for at least 6 months. * Moderate to severe disease. * Candidate for phototherapy or systemic therapy. * Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period. Exclusion Criteria * Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to \< 18 years), Part A and Part B. Participants weighing \< 18.0 kg at screening for Cohort 2 (age 4 to \< 12 years), Part A and Part B. * Other forms of psoriasis. * History of recent infection. * Prior exposure to deucravacitinib (BMS-986165) or another active comparator. * Evidence of active TB for LTE period. * Other protocol-defined inclusion/exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    48 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alberta Dermasurgery Centre

    RECRUITING

    Edmonton, Alberta, T6G 1C3, Canada

  • Arké SMO S.A de C.V

    RECRUITING

    Veracruz, 91910, Mexico

  • CCBR Clinical Research

    RECRUITING

    Bucharest, Bucharest, 30463, Romania

  • CONEXA Investigacion Clinica S.A.

    RECRUITING

    Buenos Aires, 1012, Argentina

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand-dermatology

    RECRUITING

    Dijon, 21000, France

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet

    RECRUITING

    Nice, 06202, France

  • Centre Hospitalier de Calais

    RECRUITING

    Calais, 62107, France

  • Centro de Investigaciones Metabólicas (CINME)

    RECRUITING

    Buenos Aires, C1056ABI, Argentina

  • Centro de Pesquisas da Clínica IBIS

    RECRUITING

    Salvador, Estado de Bahia, 41820-020, Brazil

  • Charité Universitaetsmedizin Berlin - Campus Mitte

    RECRUITING

    Berlin, 10117, Germany

  • Consultora Integral de Salud

    RECRUITING

    Córdoba, 5004, Argentina

  • Crea de Guadalajara

    RECRUITING

    Guadalajara, Jalisco, 44600, Mexico

  • Dermoklinika Centrum Medyczne S.C. M. Kierstan, J. Narbutt, A. Lesiak

    RECRUITING

    Lodz, 90-436, Poland

  • Fukuoka University Hospital

    RECRUITING

    Fukuoka, Jonan-Ku, Fukuoka, 814-0180, Japan

  • Grupo Clínico CATEI S.C.

    RECRUITING

    Guadalajara, Jalisco, 44638, Mexico

  • Hospital General Universitario de Alicante-Dermatology

    RECRUITING

    Alicante, 03010, Spain

  • Hospital Italiano de Buenos Aires

    RECRUITING

    CABA, 1199, Argentina

  • Hospital Moinhos de Vento

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90560-032, Brazil

  • Hospital Sant Joan de Déu-URC Dermatology

    RECRUITING

    Esplugues de Llobregat, 08950, Spain

  • Hospital Universitario 12 de Octubre-DERMATOLOGY

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario La Paz-UCICEC/DERMA

    RECRUITING

    Madrid, 28046, Spain

  • Hospital Universitario de Gran Canaria Doctor Negrín-Dermatología

    RECRUITING

    Las Palmas de GC, 35019, Spain

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFMRP

    RECRUITING

    Ribeirão Preto, São Paulo, 14051-140, Brazil

  • Instituto de Neumonologia Y Dermatologia

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, 1425, Argentina

  • Kath. Kinderkrankenhaus Wilhelmstift

    RECRUITING

    Hamburg, 22149, Germany

  • Local Institution - 0001

    COMPLETED

    Melbourne, Victoria, 3995, Australia

  • Local Institution - 0002

    WITHDRAWN

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0003

    COMPLETED

    Woolloongabba, Queensland, 4102, Australia

  • Local Institution - 0010

    COMPLETED

    Calgary, Alberta, T2J 7E1, Canada

  • Local Institution - 0011

    COMPLETED

    Krakow, 30-438, Poland

  • Local Institution - 0020

    ACTIVE_NOT_RECRUITING

    Darlinghurst, New South Wales, 2010, Australia

  • Local Institution - 0021

    COMPLETED

    Paris, 75019, France

  • Local Institution - 0029

    NOT_YET_RECRUITING

    London, London, City of, WC1N 3JH, United Kingdom

  • Local Institution - 0039

    WITHDRAWN

    Hamilton, Ontario, L8N 1Y2, Canada

  • Local Institution - 0040

    WITHDRAWN

    Isehara, Kanagawa, 259-1193, Japan

  • Local Institution - 0047

    COMPLETED

    Seoul, Seoul-teukbyeolsi [Seoul], 03722, South Korea

  • Local Institution - 0048

    COMPLETED

    Seoul, Seoul-teukbyeolsi [Seoul], 02447, South Korea

  • Local Institution - 0052

    COMPLETED

    Mexico City, Mexico City, 03100, Mexico

  • Local Institution - 0067

    WITHDRAWN

    São Paulo, 05403-000, Brazil

  • Local Institution - 0080

    WITHDRAWN

    Bucharest, Bucharest, 012292, Romania

  • Local Institution - 0081

    WITHDRAWN

    Bucharest, Bucharest, 020125, Romania

  • Local Institution - 0083

    WITHDRAWN

    Rio de Janeiro, 22470-220, Brazil

  • Local Institution - 0088

    WITHDRAWN

    Bucharest, Bucharest, 020762, Romania

  • Local Institution - 0092

    NOT_YET_RECRUITING

    London, SE1 7EH, United Kingdom

  • Lotus-Med Tunari

    RECRUITING

    Bucharest, 020528, Romania

  • Lynderm Research Inc.

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Mie University Hospital

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Monash Health

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Mounts Bay Medical

    RECRUITING

    Connor Downs, TR27 5DT, United Kingdom

  • Nagoya City University Hospital

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • Nippon Life Hospital

    RECRUITING

    Osaka, 550-0006, Japan

  • OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces-Dermatology

    RECRUITING

    Barakaldo, 48903, Spain

  • Państwowy Instytut Medyczny MSWiA-Klinika Dermatologii

    RECRUITING

    Warsaw, 02-507, Poland

  • Psoriahue

    RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425DKG, Argentina

  • Queensland Children's Hospital

    RECRUITING

    Brisbane, Queensland, 4101, Australia

  • Spitalul Clinic Judetean Mures

    RECRUITING

    Târgu Mureş, 540342, Romania

  • Spitalul clinic de urgenta pentru copii Sf. Maria

    RECRUITING

    Iași, 700309, Romania

  • Teikyo University Hospital

    RECRUITING

    Itabashi-ku, Tokyo, 173-8606, Japan

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    RECRUITING

    Seoul, Seoul-teukbyeolsi [Seoul], 06591, South Korea

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Tokyo Medical University Hospital

    RECRUITING

    Shinjuku-ku, Tokyo, 160-0023, Japan

  • Universitaetsklinikum Carl Gustav Carus Dresden

    RECRUITING

    Dresden, Saxony, 01307, Germany

  • Universitätsklinikum Münster

    RECRUITING

    Münster, North Rhine-Westphalia, 48149, Germany

  • Universitätsmedizin Johannes Gutenberg Universität Mainz

    RECRUITING

    Mainz, Rhineland-Palatinate, 55131, Germany

  • WroMedica

    RECRUITING

    Wroclaw, 51-620, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.